Atom enrolls first patient in global phase 2 trial of ABP-745 for acute gout flares

ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases

Biostar Pharma doses first patient in Phase II/III multiregional trials of utidelone capsule

Philips and Masimo partner to advance access to patient monitoring technologies

Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions

Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease

RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants

FDA grants breakthrough therapy designation to Ifinatamab Deruxtecan for lung cancer patients

Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo

AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients

The submission is supported by positive results from the Phase 3 AMPLIFY trial

UK journal publishes complex case of severe pan-drug resistant infection in US liver transplant patient successfully treated with Zaynich

This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins

Bayer’s Nubeqa receives EU approval for patients with advanced prostate cancer

European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant

There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated